Hemantha Koduri, MD
Interventional Cardiology · Lincoln, NENPI 1912055112
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Cook Incorporated at 24.8% of the total. Reporting peaked in 2020 at $3,228 and has fallen 85.8% since, to $458 in 2024.
Across 206 payments — averaging $48.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Incorporated$2K
- Medtronic$2K
- Abbott$2K
- Boston Scientific$795
- Astellas Pharma US Inc$374
- Cardiovascular Systems Inc.$366
- plus $2K from 27 others
What the payments were for
- Travel & lodging$3,30633%
- Food & beverage$3,85239%
- Education$2,83528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Incorporated | 1 | $2,474 |
| Medtronic | 28 | $2,362 |
| Abbott | 16 | $1,723 |
| Boston Scientific | 33 | $795 |
| Astellas Pharma US Inc | 5 | $374 |
| Cardiovascular Systems Inc. | 1 | $366 |
| Pfizer | 21 | $293 |
| Novartis | 21 | $281 |
| Amgen | 21 | $274 |
| Impulse Dynamics (USA) Inc. | 6 | $150 |
| Itamar Medical Inc | 2 | $104 |
| Esperion Therapeutics, Inc. | 6 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| Johnson & Johnson | 5 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Bard Peripheral Vascular, Inc. | 2 | $56 |
| Philips North America LLC | 1 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $39 |
| Lundbeck LLC | 3 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 2 | $28 |
| Gilead | 2 | $25 |
| AstraZeneca | 2 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $23 |
| Angiodynamics, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,994 in reported general payments places this provider in the 65th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $108,766 |
| XareltoRivaroxaban | 97 | $76,569 |
| EntrestoSacubitril/Valsartan | 57 | $40,660 |
| Repatha SureclickEvolocumab | 56 | $30,011 |
| BrilintaTicagrelor | 18 | $13,234 |
| JardianceEmpagliflozin | 11 | $10,306 |
| Praluent PenAlirocumab | 16 | $8,046 |
| ClopidogrelClopidogrel Bisulfate | 344 | $3,493 |
| Metoprolol Succinate | 261 | $3,489 |
| Atorvastatin Calcium | 279 | $3,343 |
| Ranolazine ErRanolazine | 35 | $2,894 |
| Nebivolol Hcl | 24 | $2,085 |
| Rosuvastatin Calcium | 173 | $1,829 |
| Carvedilol | 204 | $1,696 |
| Amlodipine Besylate | 295 | $1,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $293 | $108,766134 claims |
| Johnson & JohnsonXarelto | $67 | $76,56997 claims |
| NovartisEntresto | $281 | $40,66057 claims |
| AstraZenecaBrilinta | $24 | $13,23418 claims |
| Boehringer IngelheimJardiance | $39 | $10,30611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Lincoln
- Brock CookmanLincoln$782K
- Matthew JohnsonLincoln$162K
- Steven MartinLincoln$55K
- Natraj KattaLincoln$18K
- Denes KorpasLincoln$9K
- Harpaul BajwaLincoln$7K
- Zachary SingsankLincoln$4K
- Douglas NetzLincoln$3K
- Vishwajeth BhoopalamLincoln$3K
- Melissa AlvarezLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.